Mike Erdman

[Mike Erdman @erdapenum1]

That means 8.1% of CDT patients had a bad outcome, vs. 12.5% with anticoagulation alone (p = 0.085), making CDT no better than anticoagulation alone! #NEJM #medtwitter

[Mike Erdman @erdapenum1]

Looking at this trial of CDT vs. anticoagulation alone, the results look significant with a win for catheter directed thrombolysis, with lower incidence of the primary outcome (decompensation, death or recurrence of PE) and a slight increase in major bleeding...

[Mike Erdman @erdapenum1]

But what happens if we combine the primary efficacy outcome and the primary safety outcome to encompass all patients with "good" or "bad" (death, decompensation, recurrence or bleeding) outcomes?

[Mike Erdman @erdapenum1]

@andre339218 @ramit Is housing affordable now? Rates are the same.

[Mike Erdman @erdapenum1]

@SAEM_AEMP @MeganARech Yall should have called this series “not the SAEM: a pro/con debate” @EDWieru

[Mike Erdman @erdapenum1]

@RoryDiamond Maybe try passing some policies that voters like

[Mike Erdman @erdapenum1]

@nickmmark @neuronalnewbie Diazepam has a much shorter onset (1-3 min) compared to lorazepam (5-10) in status

[Mike Erdman @erdapenum1]

@Kylepaxoll @amandav_pharmd Bacteriostatic is a meaningless term

[Mike Erdman @erdapenum1]

@PhlawlessPharm My experience has been that community hospitals excel at the routine care but can’t handle complex patients/adverse outcomes. AMC may be less efficient but generally have better outcomes especially in complex patients.

https://t.co/TWVPBKqbSq

[Mike Erdman @erdapenum1]

@JustinUSA @JagsFanBrian Following the Trump blueprint, then.

[Mike Erdman @erdapenum1]

@PulmCrit I think study replication and publication of data sets is supposed to address this though it’s not feasible nor encouraged in the case of the former and not required in the case of the latter.

[Mike Erdman @erdapenum1]

@MrCommercial @the_transit_guy Dude you’re a transplant from WA according to your bio

[Mike Erdman @erdapenum1]

@rottengirl @the_transit_guy Never bought a car before?

[Mike Erdman @erdapenum1]

@PulmCrit The amount of studies that compare non-equivalent doses between hyperosmolar therapies is also painful.

[Mike Erdman @erdapenum1]

@PulmCrit Send me a 1099 and let’s go

[Mike Erdman @erdapenum1]

@PulmCrit This graph tho 🥴

[Mike Erdman @erdapenum1]

@cassinetobacter @BCB_PharmD They mentioned an impairment charge (write off) in Q4 2024 earnings

“The Reported SG&A expense included impairment charges of $504m recorded against the Andexxa
intangible asset”

https://t.co/GKfZHN20Rb

[Mike Erdman @erdapenum1]

@MeganARech

[Mike Erdman @erdapenum1]

@JSOPIO How is he a former officer but used his cruiser and authority to detain her?

[Mike Erdman @erdapenum1]

@AuthorJCHowell @fineout Here’s a study of studies for you to read. I agree with you about the actions of the FL SG this week.

https://t.co/HZGJ0yjfp6